Total Payments
$17,184
2023 Payments
$3,125
Companies
5
Transactions
9
Medicare Patients
3,755
Medicare Billing
$1.3M
Payment Breakdown by Category
Research$14,000 (81.5%)
Consulting$3,125 (18.2%)
Education$58.52 (0.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $14,000 | 2 | 81.5% |
| Consulting Fee | $3,125 | 2 | 18.2% |
| Education | $58.52 | 5 | 0.3% |
Payments by Type
Research
$14,000
2 transactions
General
$3,184
7 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Amgen Inc. | $14,000 | 2 | $0 (2022) |
| NOVARTIS PHARMACEUTICALS CORPORATION | $2,025 | 1 | $0 (2023) |
| E.R. Squibb & Sons, L.L.C. | $1,125 | 3 | $0 (2023) |
| Merck Sharp & Dohme Corporation | $21.74 | 2 | $0 (2021) |
| Gilead Sciences, Inc. | $11.92 | 1 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $3,125 | 2 | NOVARTIS PHARMACEUTICALS CORPORATION ($2,025) |
| 2022 | $7,513 | 2 | Amgen Inc. ($7,500) |
| 2021 | $33.66 | 3 | Merck Sharp & Dohme Corporation ($21.74) |
| 2020 | $11.41 | 1 | E.R. Squibb & Sons, L.L.C. ($11.41) |
| 2019 | $6,500 | 1 | Amgen Inc. ($6,500) |
All Payment Transactions
9 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/21/2023 | NOVARTIS PHARMACEUTICALS CORPORATION | — | Consulting Fee | Cash or cash equivalent | $2,025.00 | General |
| 08/30/2023 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $1,100.00 | General |
| 12/05/2022 | Amgen Inc. | IMLYGIC (Biological) | — | Cash or cash equivalent | $7,500.00 | Research |
| Study: P4 Registry Survival & Safety TVEC in CT • Category: Oncology | ||||||
| 09/22/2022 | E.R. Squibb & Sons, L.L.C. | OPDUALAG (Drug) | Education | In-kind items and services | $13.45 | General |
| Category: Oncology | ||||||
| 06/01/2021 | Gilead Sciences, Inc. | — | Education | In-kind items and services | $11.92 | General |
| 04/09/2021 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Education | In-kind items and services | $10.87 | General |
| Category: ONCOLOGY | ||||||
| 02/08/2021 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Education | In-kind items and services | $10.87 | General |
| Category: ONCOLOGY | ||||||
| 09/18/2020 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Education | Cash or cash equivalent | $11.41 | General |
| Category: Oncology | ||||||
| 02/22/2019 | Amgen Inc. | IMLYGIC (Biological) | — | Cash or cash equivalent | $6,500.00 | Research |
| Study: Single-arm Shedding Study (US) • Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| P4 Registry Survival & Safety TVEC in CT | Amgen Inc. | $7,500 | 1 |
| Single-arm Shedding Study (US) | Amgen Inc. | $6,500 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 24 | 708 | 10,068 | $449,671 | $51,776 |
| 2022 | 32 | 906 | 24,322 | $1.5M | $345,060 |
| 2021 | 34 | 1,046 | 38,044 | $2.0M | $476,511 |
| 2020 | 36 | 1,095 | 24,243 | $1.5M | $390,310 |
Total Patients
3,755
Total Services
96,677
Medicare Billing
$1.3M
Procedure Codes
126
All Medicare Procedures & Services
126 procedure records from CMS Medicare Utilization — Page 1 of 6
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 82 | 120 | $50,040 | $10,366 | 20.7% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 55 | 85 | $58,310 | $8,825 | 15.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 35 | 56 | $31,416 | $7,527 | 24.0% |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Office | 2023 | 11 | 34 | $133,892 | $4,272 | 3.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 45 | 59 | $16,697 | $3,636 | 21.8% |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 2023 | 13 | 7,650 | $45,900 | $3,050 | 6.6% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 44 | 138 | $14,490 | $1,716 | 11.8% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 28 | 34 | $10,336 | $1,656 | 16.0% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 16 | 16 | $8,512 | $1,610 | 18.9% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 18 | 39 | $5,967 | $1,486 | 24.9% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 63 | 146 | $2,774 | $1,219 | 44.0% |
| 84443 | Blood test, thyroid stimulating hormone (tsh) | Office | 2023 | 21 | 65 | $5,070 | $1,070 | 21.1% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 55 | 129 | $4,515 | $981.69 | 21.7% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 36 | 91 | $5,642 | $941.85 | 16.7% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 12 | 13 | $3,640 | $798.20 | 21.9% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 11 | 14 | $4,676 | $676.52 | 14.5% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 35 | 57 | $5,301 | $644.10 | 12.2% |
| 96402 | Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 13 | 15 | $2,115 | $382.78 | 18.1% |
| 82728 | Ferritin (blood protein) level | Office | 2023 | 13 | 23 | $1,334 | $307.28 | 23.0% |
| 96361 | Infusion into a vein for hydration, each additional hour | Office | 2023 | 14 | 22 | $1,606 | $214.88 | 13.4% |
| J2469 | Injection, palonosetron hcl, 25 mcg | Office | 2023 | 14 | 200 | $24,400 | $181.04 | 0.7% |
| J1626 | Injection, granisetron hydrochloride, 100 mcg | Office | 2023 | 30 | 490 | $12,250 | $147.17 | 1.2% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2023 | 33 | 560 | $560.00 | $53.90 | 9.6% |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | Office | 2023 | 11 | 12 | $228.00 | $12.20 | 5.4% |
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2022 | 18 | 6,200 | $843,200 | $255,759 | 30.3% |
About Dr. Thomas Amatruda, M.D
Dr. Thomas Amatruda, M.D is a Hematology & Oncology healthcare provider based in Fridley, Minnesota. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/09/2006. The National Provider Identifier (NPI) number assigned to this provider is 1427068618.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Thomas Amatruda, M.D has received a total of $17,184 in payments from pharmaceutical and medical device companies, with $3,125 received in 2023. These payments were reported across 9 transactions from 5 companies. The most common payment nature is "" ($14,000).
As a Medicare-enrolled provider, Amatruda has provided services to 3,755 Medicare beneficiaries, totaling 96,677 services with total Medicare billing of $1.3M. Data is available for 4 years (2020–2023), covering 126 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Fridley, MN
- Active Since 08/09/2006
- Last Updated 06/05/2015
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1427068618
Products in Payments
- IMLYGIC (Biological) $14,000
- KEYTRUDA (Biological) $21.74
- OPDUALAG (Drug) $13.45
- OPDIVO (Biological) $11.41
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.